Alcanza Clinical Research announced on April 23 the acquisition of FDI Clinical Research, a multi-specialty research organization based in San Juan, Puerto Rico, with an additional site in the west coast city of Mayagüez. Financial terms of the deal were not disclosed.
FDI Clinical Research is a state-of-the-art research facility and medical care clinic providing Phase I-IV clinical trials in support of biopharmaceutical sponsors and contract research organizations. The company specializes in a range of therapeutic areas including infectious diseases; hematology and oncology, endocrine and metabolic diseases; rheumatology and immune diseases as well as respiratory diseases.
Alcanza Clinical Research is a network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from underrepresented communities. With a network of 22 research units and several additional sites integrated within specialty clinics, it specializes in a range of conditions across psychiatry, neurology, dermatology and infectious disease therapeutic areas.
“The addition of FDI to the Alcanza site network accelerates our ability to reach more patients who are not traditionally represented with research participation opportunities across a range of increasingly prevalent diseases,” said Carlos Orantes, CEO of Alcanza. “FDI’s breadth of therapeutic expertise, access to diverse patient populations and ongoing commitment to reducing participation barriers with patient-friendly services will better enable us to deliver on our promise to customers for inclusive research.”
According to data captured in the LevinPro HC database, this acquisition represents the 12th clinical trials deal of 2024. This is an increase from last year, when there were nine transactions announced in the clinical trials specialty between January 1, 2023, and April 23, 2023.
